Business Context and Reporting Period
This Form 8-K Current Report was filed by Amneal Pharmaceuticals, Inc. (AMRX) on August 3, 2022, covering events occurring on July 29, 2022. The filing primarily addresses corporate governance changes, specifically the appointment of a new independent director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and does not contain financial performance data.
Material Changes
The material change reported is the appointment of Deborah M. Autor to the Board of Directors. The Board determined that Ms. Autor is independent under SEC rules and NYSE listing standards. She will serve until the 2023 annual meeting of stockholders and will join the Board's Conflicts Committee.
Management Commentary and Background
Ms. Autor brings significant regulatory and quality experience to the Board:
- AstraZeneca (2019-2021): Global Head of Regulatory Excellence, leading global regulatory operations, policy, and intelligence.
- Mylan N.V. (2013-2019): Head of Strategic Global Quality and Regulatory Policy and Head of Global Quality, overseeing a function of 5,000 people and 60 billion doses of medicine annually.
- U.S. FDA (2001-2013): Deputy Commissioner for Global Regulatory Operations and Policy, overseeing inspections, criminal investigations, and international operations. Previously served as Director of the Office of Compliance.
- U.S. Department of Justice: Trial Attorney in the Office of Consumer Litigation.
Ms. Autor will participate in standard non-employee director compensation programs. The filing states there are no related party transactions or family relationships between Ms. Autor and other directors or officers.
Investor Verification Checklist
- Verify the independence status of Deborah M. Autor as disclosed in the filing.
- Confirm the effective date of her board service (July 29, 2022) and term expiration (2023 annual meeting).
- Review the attached Press Release (Exhibit 99.1) for additional context on the appointment.
- Note that this filing contains no financial updates; refer to the most recent 10-Q or 10-K for financial metrics.